Table 1.
Characteristics of tested-positive Covid-19 patients treated under the new Hapvida Brazil HMO protocol.
| Given none of the medications (n = 122) | Given neither HCQ nor Prednisone (n = 244) | Given both HCQ and Prednisone (n = 159) | Given HCQ Only (n = 175) | Given Prednisone Only (n = 139) | All Patients (n = 717) | |
|---|---|---|---|---|---|---|
| Age (mean, years) (10–90 %iles) | 51.3 (41–70) | 52.0 (41–71) | 50.4 (41–60) | 50.3 (41–61) | 48.8 (4–59) | 50.6 (41–63) |
| Presentation delaya (mean, days) (10–90 %iles) | 4.1 (1–8) | 4.2 (1–8) | 4.5 (1–8) | 4.4 (1–9) | 5.6 (1–10) | 4.6 (1–9) |
| Sex (% Female) | 59.0 | 54.5 | 45.9 | 48.0 | 59.0 | 51.9 |
| Hospitalized (%) | 27.0 | 24.2 | 10.1 | 14.3 | 10.1 | 15.9 |
| Ventilated (%) | 4.9 | 3.3 | 2.5 | 1.1 | 3.6 | 2.6 |
| Died (%) | 3.3 | 2.9 | 0.6 | 0.6 | 1.4 | 1.5 |
| Cough (%) | 69.7 | 67.2 | 73.0 | 74.9 | 66.9 | 70.3 |
| Fever (%) | 52.5 | 59.4 | 66.7 | 65.7 | 61.9 | 63.0 |
| Myalgia (%) | 37.7 | 37.7 | 44.7 | 53.1 | 36.0 | 42.7 |
| Sore Throat (%) | 17.2 | 19.3 | 23.9 | 29.1 | 26.6 | 24.1 |
| Headache (%) | 36.1 | 35.7 | 41.5 | 39.4 | 41.0 | 38.9 |
| Diarrhea (%) | 7.4 | 7.4 | 8.2 | 11.4 | 11.5 | 9.3 |
| Shortness of Breath (%) | 26.2 | 30.3 | 28.9 | 28.0 | 20.9 | 27.6 |
| Type 2 Diabetes Mellitus (%) | 14.8 | 18.4 | 15.1 | 21.7 | 11.5 | 17.2 |
| Obesity (BMI>30, %) | 10.7 | 7.8 | 6.9 | 20.6 | 5.0 | 10.2 |
| Heart Disease (%) | 21.3 | 29.9 | 31.4 | 41.1 | 18.8 | 30.8 |
| Pulmonary Disease (%) | 6.6 | 4.5 | 1.3 | 4.0 | 3.6 | 3.5 |
| Given Azithromycin (%) | 0.0 | 43.4 | 50.3 | 65.7 | 58.3 | 53.3 |
| Given Ivermectin (%) | 0.0 | 24.2 | 77.4 | 42.9 | 59.7 | 47.4 |
| Given Oseltamivir (%) | 0.0 | 9.0 | 7.5 | 26.3 | 7.9 | 12.7 |
a
Number of patients with data on date of start of symptoms, 113, 222, 152, 168, 134 and 676 in the respective columns.